For Q1 FY2026 (ended March 31, 2026), Achieve Life Sciences reported a net loss of $10.2 million, an improvement of 20.7% year-over-year. Diluted EPS was -$0.19, compared to -$0.37 in the prior year period. The company held $28.1 million in cash and $10.7 million in equity as of quarter end.
•Net loss narrowed to $10.2 million from $12.8 million in Q1 FY2025.
•Diluted EPS improved to -$0.19 from -$0.37.
•Cash and cash equivalents totaled $28.1 million at March 31, 2026.
Informational summary based on SEC XBRL figures · generated by deepseek-v4-flash. Not investment advice.
Achieve Life Sciences, Inc., a late-stage pharmaceutical company develops and commercializes cytisinicline for nicotine independence in Canada, the United States, and the United Kingdom.
The company offers cytisinicline, a naturally occurring alkaloid that interacts with nicotine receptors in the brain that reduces the severity of nicotine withdrawal symptoms. It has license and supply agreements with Sopharma AD and University of Bristol. Achieve Life Sciences, Inc., is headquartered in Bothell, Washington.
Achieve Life Sciences, Inc. is a late-stage pharmaceutical company focused on developing and commercializing cytisinicline for nicotine independence. Cytisinicline is a naturally occurring alkaloid that interacts with nicotine receptors in the brain, reducing the severity of nicotine withdrawal symptoms. The company operates in Canada, the United States, and the United Kingdom. Achieve Life Sciences aims to provide a treatment option for individuals seeking to quit smoking or using other nicotine products.
Where is Achieve Life Sciences (ACHV) listed and in which currency?
Achieve Life Sciences, Inc. is listed on the Nasdaq Capital Market (NasdaqCM) under the ticker symbol ACHV. The company's stock is traded in United States Dollars (USD). As a US-based company listed on a US exchange, its financial reporting and stock price are denominated in USD, making it accessible to investors trading in US markets.
What sector and industry does Achieve Life Sciences (ACHV) operate in?
Achieve Life Sciences operates in the Healthcare sector, specifically within the Biotechnology industry. As a biotechnology company, it focuses on research, development, and commercialization of pharmaceutical products. In particular, Achieve Life Sciences is a late-stage pharmaceutical company dedicated to developing cytisinicline for nicotine independence, which falls under the broader biotechnology and pharmaceutical categories.
Where is Achieve Life Sciences (ACHV) headquartered and what markets does it serve?
Achieve Life Sciences, Inc. is headquartered in Bothell, Washington, United States. The company serves markets in Canada, the United States, and the United Kingdom. Its primary focus is on developing and commercializing cytisinicline for nicotine independence in these regions. The company has license and supply agreements with Sopharma AD and the University of Bristol to support its operations and product development.
What is the business model of Achieve Life Sciences (ACHV) and how does it generate revenue?
Achieve Life Sciences is a late-stage pharmaceutical company that generates revenue through the development and commercialization of cytisinicline for nicotine independence. The company has entered into license and supply agreements with Sopharma AD and the University of Bristol to secure the supply and intellectual property rights for cytisinicline. As a development-stage company, it likely does not yet have significant product sales revenue but may generate revenue through licensing fees, milestone payments, or partnerships. Its business model focuses on bringing cytisinicline to market as a treatment for nicotine addiction.